Author(s): King KS, Chen KX, Hulsey KM, McColl RW, Weiner MF, et al.
Purpose:To evaluate the relationship between pulse wave velocity (PWV) from the aortic arch and subsequent cerebral microvascular disease independent of other baseline cardiovascular risk factors among the participants in the multiethnic Dallas Heart Study.
Materials and methods:Each subject gave written consent to participate in this HIPAA-compliant, institutional review board-approved prospective study. Aortic arch PWV was measured with phase-contrast magnetic resonance (MR) imaging in a population sample (n = 1270) drawn from the probability-based Dallas Heart Study. Seven years later, the volume of white matter hyperintensities (WMHs) was determined from brain MR images. Linear regression was conducted with aortic arch PWV, 15 other cardiovascular risk factors, and age, sex, and ethnicity included as predictors of WMH. The authors implemented a smoothly clipped absolute deviation-penalized variable selection method to evaluate an optimal predictive risk factor model.
Results:Aortic arch PWV helped predict WMH volume independent of the other demographic and cardiovascular risk factors (regression coefficient: 0.29; standard error: 0.06; 95% confidence interval: 0.17, 0.42; P < .0001). The optimal predictor variables of subsequent WMH volume adjusted for sex and ethnicity included aortic arch PWV, age, systolic blood pressure, hypertension treatment, and congestive heart failure. The authors estimated that a 1% increase in aortic arch PWV (in meters per second) is related to a 0.3% increase in subsequent WMH volume (in milliliters) when all other variables in the model are held constant.
Conclusion:Aortic arch PWV measured with phase-contrast MR imaging is a highly significant independent predictor of subsequent WMH volume, with a higher standardized effect than any other cardiovascular risk factor assessed except for age. In an optimal predictive model of subsequent WMH burden, aortic arch PWV provides a distinct contribution along with systolic blood pressure, hypertension treatment, congestive heart failure, and age.
Referred From: https://www.ncbi.nlm.nih.gov/pubmed/23392429
Author(s): Gorelick PB, Scuteri A, Black SE, Decarli C, Greenberg SM, et al.
Author(s): Guerchet M, Aboyans V, Nubukpo P, Lacroix P, Clément JP, et al.
Author(s): Hanon O, Haulon S, Lenoir H, Seux ML, Rigaud AS, et al.
Author(s): Hilal S, Saini M, Tan CS, Catindig JA, Dong YH, et al.
Author(s): Price JF, McDowell S, Whiteman MC, Deary IJ, Stewart MC, et al.
Author(s): Sugawara N, Yasui-Furukori N, Umeda T, Kaneda A, Sato Y, et al.
Author(s): Caruana MF, Bradbury AW, Adam DJ.
Author(s): Drouet L
Author(s): Henry-Feugeas MC
Author(s): Brandts A, van Elderen SG, Westenberg JJ, van der Grond J, van Buchem MA, et al.
Author(s): Hughes TM, Kuller LH, Barinas-Mitchell EJ, Mackey RH, McDade EM, et al.
Author(s): Kuo HK, Chen CY, Liu HM, Yen CJ, Chang KJ, et al.
Author(s): Rosano C, Watson N, Chang Y, Newman AB, Aizenstein HJ, et al.
Author(s): Saji N, Kimura K, Shimizu H, Kita Y
Author(s): Saji N, Shimizu H, Kawarai T, Tadano M, Kita Y, et al.
Author(s): Tsao CW, Seshadri S, Beiser AS, Westwood AJ, Decarli C, et al.
Author(s): Bots ML, van Swieten JC, Breteler MM, de Jong PT, van Gijn J, et al.
Author(s): Debette S, Markus HS
Author(s): Ovbiagele B, Saver JL
Author(s): Pantoni L, Garcia JH
Author(s): Au R, Massaro JM, Wolf PA, Young ME, Beiser A, et al.
Author(s): Provenzano FA, Muraskin J, Tosto G, Narkhede A, Wasserman BT, et al.
Author(s): Henskens LH, Kroon AA, van Oostenbrugge RJ, Gronenschild EH, Fuss-Lejeune MM, et al.
Author(s): Mitchell GF
Author(s): Iadecola C, Park L, Capone C
Author(s): de Groot JC, de Leeuw FE, Oudkerk M, van Gijn J, Hofman A, et al.